Insider Buying: Lipocine (NASDAQ:LPCN) CEO Buys 25,000 Shares of Stock

Lipocine Inc. (NASDAQ:LPCN) CEO Mahesh Patel bought 25,000 shares of the business’s stock in a transaction that occurred on Thursday, April 2nd. The stock was purchased at an average price of $2.02 per share, with a total value of $50,500.00. Following the completion of the purchase, the chief executive officer directly owned 135,679 shares of the company’s stock, valued at $274,071.58. This represents a 22.59% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Lipocine Stock Down 77.8%

LPCN traded down $7.20 during trading on Thursday, reaching $2.05. 7,262,443 shares of the company’s stock were exchanged, compared to its average volume of 242,945. Lipocine Inc. has a fifty-two week low of $1.81 and a fifty-two week high of $12.37. The business has a 50 day moving average price of $8.62 and a 200 day moving average price of $5.77. The company has a market capitalization of $14.97 million, a P/E ratio of -1.22 and a beta of 1.09.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings data on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.26. The company had revenue of $1.15 million during the quarter, compared to analysts’ expectations of $0.12 million. Lipocine had a negative net margin of 487.00% and a negative return on equity of 59.30%.

Analyst Upgrades and Downgrades

A number of brokerages have commented on LPCN. HC Wainwright restated a “buy” rating and set a $15.00 price target (up from $7.00) on shares of Lipocine in a research note on Wednesday, January 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Lipocine in a report on Friday, March 27th. Finally, Wall Street Zen upgraded Lipocine from a “sell” rating to a “hold” rating in a research report on Sunday, March 22nd. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $15.00.

Hedge Funds Weigh In On Lipocine

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Ikarian Capital LLC bought a new stake in Lipocine during the fourth quarter worth about $1,602,000. Squadron Capital Management LLC bought a new position in shares of Lipocine in the fourth quarter valued at approximately $4,256,000. Boothbay Fund Management LLC acquired a new position in shares of Lipocine in the 4th quarter worth approximately $441,000. Diadema Partners LP acquired a new position in shares of Lipocine in the 4th quarter worth approximately $2,095,000. Finally, Persistent Asset Partners Ltd bought a new stake in Lipocine during the 4th quarter worth approximately $567,000. 9.11% of the stock is currently owned by institutional investors and hedge funds.

About Lipocine

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.